Literature DB >> 29030680

[Modern non-cosmetic treatment with botulinum toxins].

A Straube1.   

Abstract

Botulinum toxin has been known in medical history for a long time. The first scientific investigations and thoughts on possible indications in the treatment of muscular disorders were published by the German physician and poet Justinus Kerner in 1822. The physiological effect of botulinum toxin was identified in the middle of the twentieth century and the first clinical use was reported in 1977. It was first used in ophthalmology for the correction of strabismus and some years later the therapy of blepharospasm and cervical dystonia was established. Further indications, all supported by randomized controlled studies, are spastic tone increase of the limbs after lesions of the central nervous system, idiopathic axillar hyperhidrosis, chronic migraine and neurogenic or idiopathic bladder hyperactivity. In addition to these indications, a large number of further possible options have been published in the literature. Beside its effect on transmission at the neuromuscular synapses, botulinum toxin has also been shown to affect the sensory transmission of nociceptive fibers.

Entities:  

Keywords:  Afferents, muscle; Blepharospasm; Motor neurons; Nociceptive neurons; Pharmacological mechanisms of action, botulinum toxins

Mesh:

Substances:

Year:  2017        PMID: 29030680     DOI: 10.1007/s00108-017-0323-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  43 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  Botulinum toxin A for upper limb spasticity.

Authors:  Gert Kwakkel; Carel G M Meskers
Journal:  Lancet Neurol       Date:  2015-08-26       Impact factor: 44.182

3.  Botulinum toxin A in the treatment of trigeminal neuralgia.

Authors:  Jian-Hua Xia; Cai-Hong He; Hai-Feng Zhang; Ya-Jun Lian; Yuan Chen; Chuan-Jie Wu; Yun-Qing Ma
Journal:  Int J Neurosci       Date:  2015-08-18       Impact factor: 2.292

Review 4.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

5.  Facing depression with botulinum toxin: a randomized controlled trial.

Authors:  M Axel Wollmer; Claas de Boer; Nadeem Kalak; Johannes Beck; Thomas Götz; Tina Schmidt; Muris Hodzic; Ursula Bayer; Thilo Kollmann; Katja Kollewe; Daniela Sönmez; Katja Duntsch; Martin D Haug; Manfred Schedlowski; Martin Hatzinger; Dirk Dressler; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  J Psychiatr Res       Date:  2012-02-24       Impact factor: 4.791

6.  Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.

Authors:  Juan Ramirez-Castaneda; Joseph Jankovic
Journal:  Toxicon       Date:  2014-08-15       Impact factor: 3.033

7.  Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland.

Authors:  L Williams; E McGovern; O Kimmich; A Molloy; I Beiser; J S Butler; F Molloy; P Logan; D G Healy; T Lynch; R Walsh; L Cassidy; P Moriarty; H Moore; T McSwiney; C Walsh; S O'Riordan; M Hutchinson
Journal:  Eur J Neurol       Date:  2016-09-19       Impact factor: 6.089

8.  Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport.

Authors:  Laura Restani; Elena Novelli; David Bottari; Paola Leone; Ilaria Barone; Lucia Galli-Resta; Enrica Strettoi; Matteo Caleo
Journal:  Traffic       Date:  2012-05-09       Impact factor: 6.215

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.